IMMUNOLOGIC STUDIES ON SCHISTOSOMIASIS

这个项目的目的是研究免疫和免疫的机制 血吸虫病的免疫逃避，最终目标是 开发一种使用已定义抗原的实验性疫苗。 A.用纯化的副肌球蛋白进行疫苗接种试验。亲和纯化 或生化分离的副肌球蛋白被证明能提供 对挑战感染提供显著保护，每12人中有10人 使用卡介苗皮内接种的实验 血吸虫肌球蛋白或异种副肌球蛋白免疫接种 是无效的。然而，血吸虫提取物耗尽了 副肌球蛋白也具有保护性，表明存在其他 皮内模型中的重要免疫原。 疫苗识别的E/S抗原的鉴定 抗体。代谢标记的肺期血吸虫幼虫 显示能释放30、36、和100kD的四种抗原，它们是 由多次接种疫苗的小鼠特异性识别 受辐射的尾蚴。制备了一株单抗。 与100kD组分相比。这些抗原正在被 作为新的候选疫苗免疫原被研究。 C.对吡喹酮治疗的抗体依赖性。通过分析 单抗与吡喹酮治疗后的结合 从无瘤小鼠体内回收蠕虫，获得200kD的抗原 被识别为因毒品而特别暴露的人 治疗，因此是抗体的候选靶点 以前显示在吡喹酮治疗中需要有反应。

The aim of this project is to study mechanisms of immunity and immune evasion in schistosomiasis with the ultimate goal of developing an experimental vaccine employing defined antigens. A. Vaccination trials with purified paramyosin. Affinity purified or biochemically isolated paramyosin was shown to confer significant protection against challenge infection in 10 out of 12 experiments employing intradermal vaccination with BCG while vaccination with schistosome myosin or heterologous paramyosin was ineffective. However, schistosome extracts depleted of paramyosin were also protective suggesting the existence of other important immunogens in the intradermal model. B. Identification of E/S antigens recognized by vaccine antibodies. Metabolically labeled lung-stage schistosomula were shown to release four antigens of 30, 36, 64, and 100 Kd which are specifically recognized by mice multiply vaccinated with irradiated cercariae. A monoclonal antibody was produced against the 100 Kd component. These antigens are being investigated as new candidate vaccine immunogens. C. Dependence on antibody of praziquantel therapy. By assaying the binding of monoclonal antibodies to praziquantel treated worms recovered from athymic mice, an antigen of 200 Kd was identified which is specifically exposed as a result of drug treatment and therefore is a candidate target for the antibody response previously shown to be required in praziquantel therapy.